|
|
| (59 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT [[Interferon beta-1a]] |
| |genericName=Interferon Beta-1A
| |
| |aOrAn=an
| |
| |drugClass=immunologic adjuvant
| |
| |indicationType=treatment
| |
| |indication=[[multiple sclerosis]]
| |
| |adverseReactions=flu-like symptoms including chills, [[fever]], [[myalgia]], and [[asthenia]]
| |
| |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
| |
| |fdaLIADAdult='''Multiple Sclerosis, Relapsing forms'''
| |
| | |
| AVONEX (interferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
| |
| |offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Interferon Beta-1A in adult patients.
| |
| |offLabelAdultNoGuideSupport='''Multiple sclerosis, Clinically Isolated Syndrome'''
| |
| | |
| Efficacy has been demonstrated in patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
| |
| |fdaLIADPed=Safety and effectiveness in pediatric patients have not been established.
| |
| |offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Interferon Beta-1A in pediatric patients.
| |
| |offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Interferon Beta-1A in pediatric patients.
| |
| |contraindications=AVONEX is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation.
| |
| | |
| The lyophilized vial formulation of AVONEX is contraindicated in patients with a history of hypersensitivity to albumin (human).
| |
| |warnings='''Depression, Suicide, and Psychotic Disorders'''
| |
| Patients treated with AVONEX and their caregivers should be advised to report immediately any symptoms of depression, suicidal ideation, and/or psychosis to their prescribing physicians. If a patient develops depression or other severe psychiatric symptoms, cessation of AVONEX therapy should be considered.
| |
| | |
| Depression and suicide have been reported to occur with increased frequency in patients receiving AVONEX. In Study 1, the incidence of depression was similar in placebo-treated and in AVONEX-treated patients, but suicidal tendency was seen more frequently in AVONEX-treated patients (4% in AVONEX group vs. 1% in placebo group). In Study 2, there was a greater incidence of depression in AVONEX-treated patients than in placebo-treated patients (20% in AVONEX group vs. 13% in placebo group) [see Clinical Studies (14)].
| |
| | |
| Additionally, there have been post-marketing reports of depression, suicidal ideation, and/or development of new or worsening of other pre-existing psychiatric disorders, including psychosis. For some of these patients, symptoms of depression improved upon cessation of AVONEX.
| |
| |alcohol=Alcohol-Interferon Beta-1A interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| }}
| |